ELUTIA INC.
About ELUTIA INC.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- $53.4M
- Total assets
- $62.4M
- Market cap
- $44.2M
- Gross margin
- 53.7%
- Operating margin
- -218.9%
- Net margin
- 434.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $12.3M
- Cost of revenue
- $5.7M
- Gross profit
- $6.6M
- Operating expenses
- $33.5M
- Operating income
- -$26.9M
- Income tax
- $13.0K
- Net income
- $53.4M
- EPS (basic)
- $1.29
- EPS (diluted)
- $0.87
Balance sheet
- Total assets
- $62.4M
- Current assets
- $55.8M
- Total liabilities
- $34.7M
- Current liabilities
- $25.1M
- Shareholders’ equity
- $27.7M
Cash flow
- Operating cash flow
- -$44.8M
- Investing cash flow
- $78.6M
- Financing cash flow
- -$10.6M
- Net cash flow
- $23.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $44.2M
- P/E ratio
- 1.2
- EPS (diluted)
- $0.87
- Shares outstanding
- 42.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 8, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $53.4M.
- Revenue declined 50% from FY2023 to FY2025.
- Gross margin of 53.7%, net margin 434.2%.
- Trading 58% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 1.2.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ELUTIA INC..
Write a review
News about ELUTIA INC.
News & sentiment via Polygon.io
